Australia markets close in 38 minutes

    +118.10 (+1.62%)
  • ASX 200

    +119.80 (+1.70%)

    +0.0036 (+0.55%)
  • OIL

    -0.02 (-0.03%)
  • GOLD

    +4.30 (+0.21%)
  • Bitcoin AUD

    +3,046.23 (+4.81%)
  • CMC Crypto 200

    +33.87 (+3.94%)

    +0.0040 (+0.67%)

    +0.0002 (+0.02%)
  • NZX 50

    +106.50 (+0.94%)

    +38.04 (+0.24%)
  • FTSE

    -23.12 (-0.31%)
  • Dow Jones

    -79.88 (-0.22%)
  • DAX

    +128.35 (+0.78%)
  • Hang Seng

    +119.90 (+0.73%)
  • NIKKEI 225

    +572.85 (+1.75%)

The Zacks Analyst Blog Highlights Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy

For Immediate Release

Chicago, IL – October 7, 2022 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis AG NVS, Lowe's Companies, Inc. LOW, The Goldman Sachs Group, Inc. GS, Twitter, Inc. TWTR and Xcel Energy Inc. XEL

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for Novartis, Lowe's and Goldman Sachs

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Novartis AG, Lowe's Companies, Inc., and The Goldman Sachs Group, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Novartis shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-6.2% vs. +7.7%). The company is facing generic competition for key drugs, and pipeline setbacks also remain a concern.

Nevertheless, Novartis has a strong and diverse portfolio. Solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio, and the launch of Kesimpta continue to boost performance. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also boost its performance further.

The pipeline progress is also impressive, and the company has some promising candidates. Management's focus on cost savings should boost the bottom line as well. The company recently decided to spin off its generics business Sandoz into a separate entity to focus on its core pharma business.

(You can read the full research report on Novartis here >>>)

Lowe's shares have outperformed the Zacks Building Products - Retail industry over the past two years (+18.1% vs. +5.5%). The company remains well positioned to capitalize on demand for the home improvement market, backed by investments in technology, merchandise and strength in its Pro business.

Earnings performance benefited from strong operating margin, stemming from gains from the Total Home strategy and the execution of the Perpetual Productivity Improvement initiative. Focus on driving growth boosted margins.

The Total Home strategy has been resonating well with Pro and DIY customers for a while. Management is committed to enhancing its Pro offerings, expanding the company's market share and driving its operating margin.

(You can read the full research report on Lowe's here >>>)

Goldman Sachs shares have underperformed the Zacks Financial - Investment Bank industry over the past year (-21.5% vs. -15.6%). The company's decline in equities revenues is likely to hurt the Global Market segment. A rise in the expense base will hinder the bottom line. Also, legal hassles and higher dependence on overseas revenues are woes.

However, Goldman Sachs has a decent earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed in the other. The company continues to expand organically and bolster its digital consumer banking platform.

Other than business diversification, robust client engagement, a solid position in announced and completed mergers and acquisitions (M&As), and a decent investment banking (IB) backlog are likely to aid in navigating weaker markets. Also, its robust liquidity position will help sustain capital deployments.

(You can read the full research report on Goldman Sachs here >>>)

Other noteworthy reports we are featuring today include Twitter, Inc. and Xcel Energy Inc..

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
Xcel Energy Inc. (XEL) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Lowe's Companies, Inc. (LOW) : Free Stock Analysis Report
Twitter, Inc. (TWTR) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research